ERBB2 and breast carcinoma: While drugs such as trastuzumab and lapatinib have revealed significant effectiveness in treating HER-2-positive breast cancer patients [14–18], progressive drug resistance in HER-2-positive breast cancer patients has also been witnessed [19, 20].